Top

Clinical Pharmacokinetics

Published in:

01-05-2010 | Review Article

CYP-Mediated Therapeutic Protein-Drug Interactions

Clinical Findings, Proposed Mechanisms and Regulatory Implications

Authors: Dr Jang-Ik Lee, Lei Zhang, Angela Y. Men, Leslie A. Kenna, Shiew-Mei Huang

Published in: Clinical Pharmacokinetics | Issue 5/2010

Abstract

Therapeutic proteins (TPs) may affect the disposition of drugs that are metabolized by cytochrome P450 (CYP) enzymes, as is evident from a review of data in recently published literature and approved Biologic License Applications. Many TPs belonging to the cytokine class appear to differentially affect CYP activities. Cytokine modulators may affect CYP enzyme activities by altering cytokine effects on CYP enzymes. The alteration in CYP enzyme activities seems to result from changes in transcription factor activity for CYP enzyme expression or changes in CYP enzyme stability, which have been observed during altered immunological states such as infection and inflammation. Human growth hormone also appears to differentially affect CYP activities through unknown mechanisms. Because TP-drug interaction research is an evolving area, limited information is available during drug development on TP-drug interactions mediated by CYP inhibition or induction. The authors of this review suggest that effort be made to understand TP-drug interactions for the safe and effective use of TPs in combination with small-molecule drugs.

United States Public Health Service Act, Section 351, 42 USC y 262 (1944)

United States Federal Food, Drug, and Cosmetic Act, Section 505, 21 USC § 355 (1938) [online]. Available from URL: http://www.fda.gov/opacom/laws/fdcact/fdcact1.htm [Accessed 2010 Jan 25]

US FDA Center for Drug Evaluation and Research [CDER]. Guidance for industry: drug interaction studies — study design, data analysis, and implications for dosing and labeling. Rockville (MD): CDER, 2006 Sep 11 [online]. Available from URL: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm072101.pdf [Accessed 2010 Jan 25]

Huang SM, Strong JM, Zhang L, et al. New era in drug interaction evaluation: US Food and Drug Administration update on CYP enzymes, transporters, and the guidance process. J Clin Pharmacol 2008; 48: 662–70PubMedCrossRef

Huang SM, Temple R, Throckmorton DC, et al. Drug interaction studies: study design, data analysis, and implications for dosing and labeling. Clin Pharmacol Ther 2007; 81: 298–304PubMedCrossRef

US FDA Center for Drug Evaluation and Research [CDER]. Drug development and drug interactions. Silver Spring (MD): CDER, 2009 Jul 23 [online]. Available from URL: http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm080499.htm [Accessed 2010 Jan 25]

Seitz K, Zhou H. Pharmacokinetic drug-drug interaction potentials for therapeutic monoclonal antibodies: reality check. J Clin Pharmacol 2007; 47: 1104–18PubMedCrossRef

Mahmood I, Green MD. Drug interaction studies of therapeutic proteins or monoclonal antibodies. J Clin Pharmacol 2007; 47: 1540–54PubMedCrossRef

Huang SM, Zhao H, Lee JI, et al. Therapeutic protein-drug interactions and implications for drug development. Clin Pharmacol Ther 2010; 87: 497–503PubMedCrossRef

10.

Prandota J. Important role of proinflammatory cytokines/other endogenous substances in drug-induced hepatotoxicity: depression of drug metabolism during infections/inflammation states, and genetic polymorphisms of drug-metabolizing enzymes/cytokines may markedly contribute to this pathology. Am J Ther 2005; 12: 254–61PubMed

11.

Morgan ET. Regulation of cytochromes P450 during inflammation and infection. Drug Metab Rev 1997; 29: 1129–88PubMedCrossRef

12.

Morgan ET, Goralski KB, Piquette-Miller M, et al. Regulation of drug-metabolizing enzymes and transporters in infection, inflammation, and cancer. Drug Metab Dispos 2008; 36: 205–16PubMedCrossRef

13.

Morgan ET. Impact of infectious and inflammatory disease on cytochrome P450-mediated drug metabolism and pharmacokinetics. Clin Pharmacol Ther 2009; 85: 434–8PubMedCrossRef

14.

Chang KC, Bell TD, Lauer BA, et al. Altered theophylline pharmacokinetics during acute respiratory viral illness. Lancet 1978; 1: 1132–3PubMedCrossRef

15.

Kraemer MJ, Furukawa CT, Koup JR, et al. Altered theophylline clearance during an influenza B outbreak. Pediatrics 1982; 69: 476–80PubMed

16.

Renton KW, Deloria LB, Mannering GJ. Effects of polyribonoinosinic acid polyribocytidylic acid and a mouse interferon preparation on cytochrome P-450-dependent monooxygenase systems in cultures of primary mouse hepatocytes. Mol Pharmacol 1978; 14: 672–81PubMed

17.

Mayo PR, Skeith K, Russell AS, et al. Decreased dromotropic response to verapamil despite pronounced increased drug concentration in rheumatoid arthritis. Br J Clin Pharmacol 2000; 50: 605–13PubMedCrossRef

18.

Strehlau J, Pape L, Offner G, et al. Interleukin-2 receptor antibody-induced alterations of ciclosporin dose requirements in paediatric transplant recipients. Lancet 2000; 356: 1327–8PubMedCrossRef

19.

Aitken AE, Richardson TA, Morgan ET. Regulation of drug-metabolizing enzymes and transporters in inflammation. Annu Rev Pharmacol Toxicol 2006; 46: 123–49PubMedCrossRef

20.

Ashino T, Oguro T, Shioda S, et al. Involvement of interleukin-6 and tumor necrosis factor alpha in CYP3A11 and 2C29 down-regulation by Bacillus Calmette-Guerin and lipopolysaccharide in mouse liver. Drug Metab Dispos 2004; 32: 707–14PubMedCrossRef

21.

El-Kadi AO, Bleau AM, Dumont I, et al. Role of reactive oxygen intermediates in the decrease of hepatic cytochrome P450 activity by serum of humans and rabbits with an acute inflammatory reaction. Drug Metab Dispos 2000; 28: 1112–20PubMed

22.

Renton KW. Alteration of drug biotransformation and elimination during infection and inflammation. Pharmacol Ther 2001; 92: 147–63PubMedCrossRef

23.

Williams SJ, Baird-Lambert JA, Farrell GC. Inhibition of theophylline metabolism by interferon. Lancet 1987; 330: 939–41CrossRef

24.

Williams SJ, Farrell GC. Inhibition of antipyrine metabolism by interferon. Br J Clin Pharmacol 1986; 22: 610–2PubMedCrossRef

25.

Becquemont L, Chazouilleres O, Serfaty L, et al. Effect of interferon alpha-ribavirin bitherapy on cytochrome P450 1A2 and 2D6 and N-acetyl-transferase-2 activities in patients with chronic active hepatitis C. Clin Pharmacol Ther 2002; 71: 488–95PubMedCrossRef

26.

Pageaux GP, le Bricquir Y, Berthou F, et al. Effects of interferon-alpha on cytochrome P-450 isoforms 1A2 and 3A activities in patients with chronic hepatitis C. Eur J Gastroenterol Hepatol 1998; 10: 491–5PubMedCrossRef

27.

Islam M, Frye RF, Richards TJ, et al. Differential effect of IFNalpha-2b on the cytochrome P450 enzyme system: a potential basis of IFN toxicity and its modulation by other drugs. Clin Cancer Res 2002; 8: 2480–7PubMed

28.

Craig PI, Tapner M, Farrell GC. Interferon suppresses erythromycin metabolism in rats and human subjects. Hepatology 1993; 17: 230–5PubMedCrossRef

29.

Wong SF, Jakowatz JG, Taheri R. Potential drug-drug interaction between interferon alfa-2b and gemfibrozil in a patient with malignant melanoma. Clin Ther 2005; 27: 1942–8PubMedCrossRef

30.

Okuno H, Takasu M, Kano H, et al. Depression of drug-metabolizing activity in the human liver by interferon-beta. Hepatology 1993; 17: 65–9PubMedCrossRef

31.

Aitken AE, Morgan ET. Gene-specific effects of inflammatory cytokines on cytochrome P450 2C, 2B6 and 3A4 mRNA levels in human hepatocytes. Drug Metab Dispos 2007; 35: 1687–93PubMedCrossRef

32.

Elkahwaji J, Robin MA, Berson A, et al. Decrease in hepatic cytochrome P450 after interleukin-2 immunotherapy. Biochem Pharmacol 1999; 57: 951–4PubMedCrossRef

33.

Tinel M, Robin MA, Doostzadeh J, et al. The interleukin-2 receptor down-regulates the expression of cytochrome P450 in cultured rat hepatocytes. Gastroenterology 1995; 109: 1589–99PubMedCrossRef

34.

Frye RF, Schneider VM, Frye CS, et al. Plasma levels of TNF-alpha and IL-6 are inversely related to cytochrome P450-dependent drug metabolism in patients with congestive heart failure. J Card Fail 2002; 8: 315–9PubMedCrossRef

35.

Chen YL, Le Vraux V, Leneveu A, et al. Acute-phase response, interleukin-6, and alteration of cyclosporine pharmacokinetics. Clin Pharmacol Ther 1994; 55: 649–60PubMedCrossRef

36.

Knüpfer H, Schmidt R, Stanitz D, et al. CYP2C and IL-6 expression in breast cancer. Breast 2004; 13: 28–34PubMedCrossRef

37.

Gorski JC, Hall SD, Becker P, et al. In vivo effects of interleukin-10 on human cytochrome P450 activity. Clin Pharmacol Ther 2000; 67: 32–43PubMedCrossRef

38.

Glassman AH, Johnson LL, Giardina EG, et al. The use of imipramine in depressed patients with congestive heart failure. JAMA 1983; 250: 1997–2001PubMedCrossRef

39.

Winkelhake JL, Gauny SS. Human recombinant interleukin-2 as an experimental therapeutic. Pharmacol Rev 1990; 42: 1–28PubMed

40.

Moore KW, O’Garra A, de Waal MR, et al. Interleukin-10. Annu Rev Immunol 1993; 11: 165–90PubMedCrossRef

41.

Sifontis NM, Benedetti E, Vasquez EM. Clinically significant drug interaction between basiliximab and tacrolimus in renal transplant recipients. Transplant Proc 2002; 34: 1730–2PubMedCrossRef

42.

Vasquez EM, Pollak R. OKT3 therapy increases cyclosporine blood levels. Clin Transplant 1997; 11: 38–41PubMed

43.

Chatenoud L, Ferran C, Reuter A, et al. Systemic reaction to the anti-T-cell monoclonal antibody OKT3 in relation to serum levels of tumor necrosis factor and interferon-gamma [published erratum appears in N Engl J Med 1989; 321: 63]. N Engl J Med 1989; 320: 1420–1PubMedCrossRef

44.

Abramowicz D, Schandene L, Goldman M, et al. Release of tumor necrosis factor, interleukin-2, and gamma-interferon in serum after injection of OKT3 monoclonal antibody in kidney transplant recipients. Transplantation 1989; 47: 606–8PubMedCrossRef

45.

Hoffmann-La Roche Inc. Briefing document for tocilizumab biologic license application 125276. Nutley (NJ): Hoffmann-La Roche Inc., 2008 Jul 2 [online]. Available from URL: http://www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4371b1-02-Roche.pdf [Accessed 2010 Jan 25]

46.

Zhang X, Achmitt S, Grange S, et al. Disease-drug interaction studies of tocilizumab with cytochrome P450 substrates in vitro and in vivo [abstract]. Clin Pharmacol Ther 2009; 85: S59CrossRef

47.

Actemra® (tocilizumab): package insert. South San Francisco (CA): Genentech Inc., 2010 Jan 10 [online]. Available from URL: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/125276lbl.pdf [Accessed 2010 Mar 21]

48.

Jürgens G, Lange KH, Reuther LO, et al. Effect of growth hormone on hepatic cytochrome P450 activity in healthy elderly men. Clin Pharmacol Ther 2002; 71: 162–8PubMedCrossRef

49.

Cheung NW, Liddle C, Coverdale S, et al. Growth hormone treatment increases cytochrome P450-mediated antipyrine clearance in man. J Clin Endocrinol Metab 1996; 81: 1999–2001PubMedCrossRef

50.

Levitsky LL, Schoeller DA, Lambert GH, et al. Effect of growth hormone therapy in growth hormone-deficient children on cytochrome P-450-dependent 3-N-demethylation of caffeine as measured by the caffeine 13CO2 breath test. Dev Pharmacol Ther 1989; 12: 90–5PubMed

51.

Redmond GP, Bell JJ, Perel JM. Effect of human growth hormone on amobarbital metabolism in children. Clin Pharmacol Ther 1978; 24: 213–8PubMed

52.

Redmond GP, Bell JJ, Nichola PS, et al. Effect of growth hormone on human drug metabolism: time course and substrate specificity. Pediatr Pharmacol (New York) 1980; 1: 63–70

53.

Roferon®-A (interferon alfa-2a, recombinant): package insert. Nutley (NJ): Hoffman La Roche Inc., 2006 Aug 29 [online]. Available from URL: http://www.accessdata.fda.gov/drugsatfda_docs/label/2006/103145s5060LBL.pdf [Accessed 2010 Jan 25]

54.

Jonkman JH, Nicholson KG, Farrow PR, et al. Effects of alpha-interferon on theophylline pharmacokinetics and metabolism. Br J Clin Pharmacol 1989; 27: 795–802PubMedCrossRef

55.

Intron® A (interferon alfa-2b, recombinant for injection): package insert. Kenilworth (NJ): Schering Corporation, 2007 Jul 13 [online]. Available from URL: http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/103132s5096lbl.pdf [Accessed 2010 Jan 25]

56.

PegIntron (peginterferon alfa-2b injection, powder for solution for subcutaneous use): package insert. Kenilworth (NJ): Schering Corporation, 2009 Mar 10 [online]. Available from URL: http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/103949s5172lbl.pdf [Accessed 2010 Jan 25]

57.

Arcalyst® (rilonacept injection for subcutaneous use): package insert. Tarry-town (NJ): Regeneron Pharmaceuticals, Inc., 2008 Feb 27 [online]. Available from URL: http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/125249lbl.pdf [Accessed 2010 Jan 25]

58.

Ilaris® (canakinumab): package insert. East Hanover (NJ): Novartis Pharmaceuticals Corp., 2009 Jun 17 [online]. Available from URL: http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/125319s000lbl.pdf [Accessed 2010 Mar 21]

59.

Simponi® (golimumab): package insert. Horsham (PA): Centocor Ortho Biotech Inc., 2009 Nov 18 [online]. Available from URL: http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/125289s006lbl.pdf [Accessed 2010 Mar 21]

60.

Stelara® (ustekinumab): package insert. Horsham (PA): Centocor Ortho Biotech Inc., 2009 Dec 30 [online]. Available from URL: http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/125261s001lbl.pdf [Accessed 2010 Mar 21]

61.

Drugs@FDA: somatropin package inserts [online]. Available from http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm [Accessed 2010 Jan 25]

62.

Zhang L, Zhang YD, Zhao P, et al. Predicting drug-drug interactions: an FDA perspective. AAPS J 2009; 11: 300–6PubMedCrossRef

Title: CYP-Mediated Therapeutic Protein-Drug Interactions
Clinical Findings, Proposed Mechanisms and Regulatory Implications
Authors: Dr Jang-Ik Lee
Lei Zhang
Angela Y. Men
Leslie A. Kenna
Shiew-Mei Huang
Publication date: 01-05-2010
Publisher: Springer International Publishing
Published in: Clinical Pharmacokinetics / Issue 5/2010
Print ISSN: 0312-5963
Electronic ISSN: 1179-1926
DOI: https://doi.org/10.2165/11319980-000000000-00000

At a glance: The STEP trials

Springer Medicine

CYP-Mediated Therapeutic Protein-Drug Interactions

Clinical Findings, Proposed Mechanisms and Regulatory Implications

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2010

Effects of Hypothermia on Pharmacokinetics and Pharmacodynamics

Pharmacokinetics and Pharmacodynamics of Propiverine in Children Aged between 5 and 10 Years with Symptoms of Overactive Bladder

Pharmacokinetics of Multiple-Dose Darunavir in Combination with Low-Dose Ritonavir in Individuals with Mild-to-Moderate Hepatic Impairment

Kinetics of Imipenem Distribution into the Peritoneal Fluid of Patients with Severe Peritonitis Studied by Microdialysis

Effects of Varying Degrees of Renal Impairment on the Pharmacokinetics of Duloxetine